The Breakthrough Team represents an unprecedented opportunity to bring together the best scientific minds from diverse fields of research to concentrate on new approaches to address health equity in the context of cancer research.
The goal of SU2C “health equity” is for patients of all racial and ethnic backgrounds to equally benefit from the potential of cancer treatments; and for cancer research to address remediable differences, i.e., genetics, biology, risk, incidence, and mortality, and barriers to participation, in order to attain comparable outcomes for all racial and ethnic populations. This Breakthrough Team will be unique in that it brings together key stakeholders that are deeply connected to the impacted communities and will integrate social/behavioral determinants of health and outreach with cancer biology, prevention, and treatment. The Breakthrough Team is supported by a transformational grant from Genentech, a member of the Roche Group. The scale of a project should not exceed US $6 million total. Teams are required to have a Team Leader, Team Co-Leader, Project Manager, and two Patient Advocates. Research must be carried out within the United States. There are no citizenship or residency status restrictions for team members.
- Please submit* your “Letter of Intent” by Tuesday, September 1, 2020, at 12pm Noon EDT. Finalists will be invited on or before Thursday, October 1, 2020, to submit a full application due Friday, January 8, 2021.
- Projects should be planned for four years with any proposed clinical trials completing accrual by the end of the grant period.
URL for more Information:
If you have questions, please contact firstname.lastname@example.org.
Filed Under: Funding Opportunities